Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Hematologic Malignancy Reports
Published in: Current Hematologic Malignancy Reports 6/2017

01-12-2017 | Invited Commentary

Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond

Author: Naveen Pemmaraju

Published in: Current Hematologic Malignancy Reports | Issue 6/2017

Login to get access

Excerpt

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a historically rare hematologic malignancy with poor overall outcomes, a challenging pathologic and clinical presentation, and no consensus therapeutic approach [1]. After decades of changing nomenclature (e.g., CD4+CD56+ hematodermic tumor, blastic NK cell lymphoma), the WHO ultimately solidified the name “BPDCN” and placed it under “Acute myeloid leukemia (AML) and related family of neoplasms” in 2008 [2]. With increasing understanding of BPDCN, further recognition of its distinct clinical presentation and course, and evolving molecular insights, the disease has now been designated as its own separate category under myeloid malignancies in the latest WHO re-classification schema [3]. …
Literature
1.
Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2016;14:220–2.PubMed
2.
Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.CrossRefPubMed
3.
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRefPubMed
4.
Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19:1006–12.CrossRefPubMed
5.
Pemmaraju N, Thomas D, Kantarjian HM, et al. Analysis of outcomes of patients with blastic plasmacytoid dendritic cell neoplasm. ASH Annual Meeting Abstracts. 2012;120:3554.
6.
Pagano L, Valentini CG, Grammatico S, Pulsoni A. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174:188–202.CrossRefPubMed
7.
Brunetti L, Di Battista V, Venanzi A, et al. Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin. Leukemia. 2017;31:1238–40.CrossRefPubMed
8.
Aoki T, Suzuki R, Kuwatsuka Y, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125:3559–62.CrossRefPubMed
9.
Roos-Weil D, Dietrich S, Boumendil A, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121:440–6.CrossRefPubMed
10.
Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777–84.CrossRefPubMed
11.
12.
Frankel A. Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies. ASCO Annual Meeting 2013. J Clin Oncol (Meeting Abstracts). 2013;31(15_suppl):7029.
13.
Pemmaraju N et al. Results from phase 2 trial ongoing expansion stage of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood (ASH abstract #4245, Dec 2016) 2016.
14.
Pemmaraju NLA, Sweet KL, Stein A, Sumithira V, Blum WG. Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): lead-in completed, expansion stage ongoing. J Clin Oncol 2016; 34 (suppl; abstr 7006).
15.
Cai T, Galetto R, Gouble A, et al. Pre-clinical studies of anti-CD123 CAR-T cells for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood. 2016;128:4039.CrossRef
16.
Mardiros A, Dos Santos C, McDonald T, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122:3138–48.CrossRefPubMedPubMedCentral
17.
Nievergall E, Ramshaw HS, Yong AS, et al. Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014;123:1218–28.CrossRefPubMed
18.
19.
Tasian SK, Kenderian SS, Shen F, et al. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood. 2017;129:2395–407.CrossRefPubMed
20.
Seung Y, Chu EP, Chen H, Phung S, Chan EW, Endo NA, et al. Immunotherapy with long-lived anti-CD123 × anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human AML cell lines and of CD123+ cells in monkeys: a potential therapy for acute myelogenous leukemia. Blood (ASH abstract). 2014;124:2316.CrossRef
21.
Al-Hussaini M, Rettig MP, Ritchey JK, et al. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. Blood. 2016;127:122–31.CrossRefPubMedPubMedCentral
22.
Sapienza MR, Fabio F, Claudio A, et al. Molecular profiling of blastic plasmacytoid dendritic CELL neoplasm reveals a unique pattern and suggests selective sensitivity to NF-KB pathway inhibition. Blood. 2013;122:2502.
23.
24.
Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–8.CrossRefPubMed
25.
Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia.
26.
Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer discovery. 2016;6:1106–17.CrossRefPubMedPubMedCentral
27.
Montero J, Stephansky J, Cai T, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax. Cancer Discovery. 2017;7:156–64.CrossRefPubMed
28.
29.
30.
31.
Ott CJ, Kopp N, Bird L, et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012;120:2843–52.CrossRefPubMedPubMedCentral
32.
Emadali A, Hoghoughi N, Duley S, et al. Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms. Blood. 2016;127:3040–53.CrossRefPubMedPubMedCentral
33.
Ceribelli M, Hou ZE, Kelly PN, et al. A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell. 2016;30:764–78.CrossRefPubMedPubMedCentral
Metadata
Title
Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond
Author
Naveen Pemmaraju
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Hematologic Malignancy Reports / Issue 6/2017
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-017-0425-7

Other articles of this Issue 6/2017

Current Hematologic Malignancy Reports 6/2017 Go to the issue

Myelodysplastic Syndromes (M Savona, Section Editor)

Models of Prognostication in Chronic Myelomonocytic Leukemia

Invited Commentary

Prognostication and Initiation of Therapy in Polycythemia Vera: Do We Have it Right?

Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN

CART and Immunotherapy (M Ruella, Section Editor)

Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer

Acute Myeloid Leukemias (H Erba, Section Editor)

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia

Acute Myeloid Leukemias (H Erba, Section Editor)

Diagnostic and Prognostic Utility of Fluorescence In situ Hybridization (FISH) Analysis in Acute Myeloid Leukemia
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits